CollPlant Biotechnologies (FRA:CPT) 3-Year Share Buyback Ratio : -2.10% (As of Mar. 2025)

View and export this data going back to 2021. Start your Free Trial

What is CollPlant Biotechnologies 3-Year Share Buyback Ratio?

Shares Outstanding (EOP) are shares that have been authorized, issued, and purchased by investors and are held by them.

3-Year Share Buyback Ratio measures the average annual proportion of a company's outstanding shares repurchased over the past three years. It is calculated as the annualized percentage change in shares outstanding from three years ago to the current year. A positive ratio may indicate share buybacks over the period, while a zero or negative ratio may reflect no repurchases or potential share issuance. CollPlant Biotechnologies's current 3-Year Share Buyback Ratio was -2.10%.

The historical rank and industry rank for CollPlant Biotechnologies's 3-Year Share Buyback Ratio or its related term are showing as below:

FRA:CPT' s 3-Year Share Buyback Ratio Range Over the Past 10 Years
Min: -41.3 Med: -26.45 Max: 76
Current: -2.1

During the past 13 years, CollPlant Biotechnologies's highest 3-Year Share Buyback Ratio was 76.00%. The lowest was -41.30%. And the median was -26.45%.

FRA:CPT's 3-Year Share Buyback Ratio is ranked better than
75.85% of 1263 companies
in the Biotechnology industry
Industry Median: -9.8 vs FRA:CPT: -2.10

Competitive Comparison of CollPlant Biotechnologies's 3-Year Share Buyback Ratio

For the Biotechnology subindustry, CollPlant Biotechnologies's 3-Year Share Buyback Ratio, along with its competitors' market caps and 3-Year Share Buyback Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

CollPlant Biotechnologies's 3-Year Share Buyback Ratio Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, CollPlant Biotechnologies's 3-Year Share Buyback Ratio distribution charts can be found below:

* The bar in red indicates where CollPlant Biotechnologies's 3-Year Share Buyback Ratio falls into.

Save Embed

;

Save Embed

;

CollPlant Biotechnologies 3-Year Share Buyback Ratio Calculation

This is the annualized percentage change in shares outstanding from three years ago to the current year. The annualized percentage change is calculated with expontential compound based on the latest four years of annual data on Shares Outstanding (EOP).

Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average dividends per share growth rate.

CollPlant Biotechnologies (FRA:CPT) 3-Year Share Buyback Ratio Explanation

A negative number means the company might be issuing new shares. A positive number indicates that the company is buying back shares.

Be Aware

Investors usually like share buybacks. But as pointed by Warren Buffett, only if a company buys back shares at the prices below the stock's intrinsic value, it rewards remaining shareholders. If a company buys its overvalued stocks back, it destroys shareholder value.

CollPlant Biotechnologies 3-Year Share Buyback Ratio Related Terms

Thank you for viewing the detailed overview of CollPlant Biotechnologies's 3-Year Share Buyback Ratio provided by GuruFocus.com. Please click on the following links to see related term pages.

CollPlant Biotechnologies Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » CollPlant Biotechnologies Ltd (FRA:CPT) » Definitions » 3-Year Share Buyback Ratio

Comparable Companies

Traded in Other Exchanges

CLGN:USA

Address

4 Oppenheimer Street, P.O. Box 4132, Weizmann Science Park, Rehovot, ISR, 7670104

Website

https://www.collplant.com

CollPlant Biotechnologies Ltd is a regenerative and aesthetic medicine company focused on 3D bioprinting of tissues and organs and medical aesthetics. Its products are based on its rhCollagen (recombinant human collagen) produced with CollPlant's proprietary plant based genetic engineering technology. These products address indications for the diverse fields of tissue repair, aesthetics, and organ manufacturing. The revenues include income from business collaborators and sales of the BioInk product for the development of 3D bioprinting of organs and tissues, sales of rhCollagen for the medical aesthetics market, and sales in Europe of the products for tendinopathy and wound healing. The company operates in United States, which derives key revenue, Canada, Europe and Other, and Israel.